ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.

ABECMA® Information and Resources for Nurses

As a nurse, you play a critical role in the ABECMA treatment process, helping RRMM patients navigate their journey with ABECMA. Get the information and tools you need to help support your patients below.

From clinical trial data to monitoring and management information, it’s all here—so you can continue to help your patients feel comfortable and secure throughout their treatment journey.

RRMM=relapsed/refractory multiple myeloma.

Depend on the ABECMA® Treatment Process

The ABECMA treatment journey involves many steps, and it requires close collaboration between a patient’s primary oncologist and a certified ABECMA treatment center. You play an integral role as part of the multidisciplinary team that supports both patients and caregivers throughout their ABECMA treatment journey.

Help your patient understand the ABECMA treatment process and the care team they may encounter throughout their journey

The Learn How ABECMA Is Made video can help your patients understand the ABECMA treatment process

The Meet your ABECMA Care Team video can help educate your patients on the many different care team members they will encounter

Watch in Spanish

ABECMA treatment

See a detailed overview of the ABECMA treatment process below.

Document Icon
See the ABECMA
Clinician Guide for Nurses

for further information on the
ABECMA process.


Expand All

  • Patient eligibility and initiation1

    • Eligible adult patients include those who are triple-class exposed (patients who have received an IMiD® agent, a PI, and an anti-CD38 monoclonal antibody) and who have received at least 4 prior lines of therapy
  • Leukapheresis1,2

    • You will help collect your patient’s T cells via leukapheresis
    • Your patient will need to stop systemic MM therapy (including experimental agents) and corticosteroids (>20 mg/day prednisone or equivalent) ≥14 days prior to leukapheresis
  • Manufacturing1

    • Your patient’s cells are sent to a manufacturing site for engineering and expansion to the recommended dose
    • ABECMA is an autologous product; the manufactured dose for individual patients may vary
    • Your patient’s dose will be 300 to 460 x 106 CAR-positive T cells
    • Bridging therapy can be used in some patients at the care team’s discretion for disease control during the manufacturing process


    Manufacturing success rate in the pivotal study1*


    Target turnaround time for commercial manufacturing (for >90% of batches)1†

  • Shipping and receipt3

    • To ensure patient safety, Bristol Myers Squibb requires chain of identity (COI) at 4 key points in the treatment process: when you receive the LN2 dry vapor shipper; after transferring ABECMA to on-site storage; prior to thawing ABECMA; and prior to ABECMA administration
    • On the scheduled date, ABECMA will be shipped directly to the infusion site’s assigned address and/or department, as specified on the Cell Therapy 360® Scheduling Portal
    • Cryopreserved ABECMA will be shipped to your site in a LN2 dry vapor shipper
  • Storage3

    • The method of storage will depend on the individual site's capabilities: Just-in-time delivery (ABECMA arrives on or near the date of infusion and remains in the LN2 dry vapor shipper until the product is thawed for patient administration) or on-site storage by preapproval process (ABECMA is transferred to on-site vapor-phase LN2 storage)
  • Lymphodepleting chemotherapy1,2,4

    • You will begin administration of low-dose lymphodepleting chemotherapy 5 days before the patient’s scheduled ABECMA infusion (low-dose fludarabine [30 mg/m2 IV infusion] and cyclophosphamide [300 mg/m2 IV infusion] daily for 3 days)
    • The care team is notified of the estimated ABECMA delivery date. Product availability should be confirmed prior to starting lymphodepletion
    • Stop MM bridging therapies (following leukapheresis) ≥14 days prior to lymphodepleting chemotherapy

  • Premedication1

    • 30 to 60 minutes before ABECMA infusion, you should administer acetaminophen (650 mg orally) and diphenhydramine (12.5 mg IV or 25 to 50 mg orally, or another H1-antihistamine)
  • Thawing3

    • Each infusion bag must be infused within 1 hour of the start of its thaw
    • See the ABECMA Clinician Guide for Nurses for detailed instructions on thawing ABECMA infusion bags
  • Infusion1,3

    • You will administer ABECMA 2 days after your patient completes lymphodepletion
    • ABECMA is provided as a single dose for infusion containing a suspension of CAR-positive T cells in 1 or more infusion bags
    • Step 1: Infuse the contents of the infusion bag by gravity flow
    • Step 2: After the entire contents of the infusion bag have been infused, flush the tubing with 30 to 60 mL of normal saline at the same infusion rate to ensure all the cells are delivered
    • Step 3: If more than 1 infusion bag is being administered, repeat the procedure (thawing through saline flush) to administer subsequent infusion bags of ABECMA in series
    • Keep the remaining bag(s) in LN2 storage until prior bag has been infused and patient is ready; proceed to the subsequent infusion bag based on clinical judgment


When CRS and NT are more likely to occur

First 7 days after infusion

Monitoring at the treatment center

Most cases of CRS and NT occurred soon after infusion and resolved quickly in the clinical trial.

  • You and your care team will monitor patients for signs and symptoms of CRS and NT for 7 days following infusion at the REMS-certified healthcare facility


When CRS is less likely to occur

Monitoring near the treatment center

During this time, your patient and their caregiver will be staying within 2 hours of the treatment center; for example, at a hotel.

They will work together to keep track of any symptoms that may arise.

Topics to discuss with your patient
  • Alerting their caregiver if they have symptoms of CRS or NT
  • Completing daily monitoring tests
  • Attending appointments at the treatment center
Topics to discuss with your patient's caregiver
  • Taking the patient's temperature at least 3 times a day
  • Doing a cognitive test
  • Monitoring the patient with tests as described by the ABECMA care team
  • Calling the ABECMA care team if the patient experiences any symptoms
  • Taking the patient to scheduled appointments at the treatment center


When CRS is less likely to occur

Long-term monitoring at home

After at least 4 weeks of monitoring at or near the treatment center, your patient may return to their primary oncologist for continued monitoring and routine care appointments.

Week 1

When CRS is
more likely to

When NT is
more likely to

Weeks 2-4+

When CRS is
less likely to

The manufacturing success rate is defined as the ability to manufacture the product. The risk of manufacturing failure was 1.5% (2/135) in the pivotal study.

Manufacturing turnaround times may vary. The median time from leukapheresis to product availability was 33 days (range: 26 to 49 days).

CAR=chimeric antigen receptor; CRS=cytokine release syndrome; IV=intravenous; LN2=liquid nitrogen; MM=multiple myeloma; NT=neurologic toxicity; PI=proteasome inhibitor; REMS=Risk Evaluation and Mitigation Strategy.

Learn more about ABECMA

See more ABECMA safety